MCID: HYP025
MIFTS: 47

Hyperphosphatemia

Categories: Metabolic diseases

Aliases & Classifications for Hyperphosphatemia

MalaCards integrated aliases for Hyperphosphatemia:

Name: Hyperphosphatemia 12 29 54 44 15 70

Classifications:



External Ids:

Disease Ontology 12 DOID:0050459
MeSH 44 D054559
NCIt 50 C113750
SNOMED-CT 67 20165001
UMLS 70 C0085681

Summaries for Hyperphosphatemia

Disease Ontology : 12 A phosphorus metabolism disease characterized by hyperphosphatemia and abnormal deposits of phosphate and calcium in joints and soft tissues, results from abnomral phosphorus metabolism and has material basis in mutations in the FGF23, GALNT3 or KL gene.

MalaCards based summary : Hyperphosphatemia is related to tumoral calcinosis, hyperphosphatemic, familial, 1 and pseudohypoparathyroidism, type ib. An important gene associated with Hyperphosphatemia is FGF23 (Fibroblast Growth Factor 23), and among its related pathways/superpathways are Mesenchymal Stem Cell Differentiation Pathways and Lineage-specific Markers and Endochondral Ossification. The drugs Atorvastatin and Sodium citrate have been mentioned in the context of this disorder. Affiliated tissues include kidney, bone and smooth muscle, and related phenotypes are cardiovascular system and homeostasis/metabolism

Wikipedia : 73 Hyperphosphatemia is an electrolyte disorder in which there is an elevated level of phosphate in the... more...

Related Diseases for Hyperphosphatemia

Diseases related to Hyperphosphatemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 264)
# Related Disease Score Top Affiliating Genes
1 tumoral calcinosis, hyperphosphatemic, familial, 1 32.9 PTH PHEX KL GALNT3 FGF23
2 pseudohypoparathyroidism, type ib 32.0 STX16 PTH GNAS BGLAP
3 familial tumoral calcinosis 32.0 PHEX KL GALNT3 FGF23
4 pseudohypoparathyroidism, type ia 31.8 STX16 PTH GNAS
5 pseudohypoparathyroidism 31.6 STX16 PTH GNAS BGLAP
6 hypoparathyroidism-retardation-dysmorphism syndrome 31.5 PTH GCM2 CASR
7 hypoparathyroidism 31.0 VDR PTH GNAS GCM2 FGF23 CASR
8 hypocalcemia, autosomal dominant 1 30.9 VDR PTH GNAS GCM2 FGF23 CASR
9 metabolic acidosis 30.6 PTH FGF23 BGLAP ALB
10 hyperostosis 30.4 SPP1 KL GALNT3 FGF23
11 secondary hyperparathyroidism 30.2 VDR PTH PHEX KL FGF23 CASR
12 hyperparathyroidism 30.2 VDR PTH PHEX KL GCM2 FGF23
13 hyperuricemia 30.1 PTH CRP ALB
14 deficiency anemia 30.1 PTH GNAS FGF23 CRP ALB
15 oncogenic osteomalacia 30.1 SFRP4 PTH PHEX FGF23
16 renal osteodystrophy 29.9 VDR PTH MGP FGF23 CASR BGLAP
17 hypophosphatemic rickets, x-linked recessive 29.9 VDR SLC34A1 SFRP4 PHEX FGF23
18 hypervitaminosis d 29.8 VDR PTH KL GALNT3 FGF23
19 intestinal obstruction 29.8 MTOR CRP ALB
20 fanconi syndrome 29.7 SLC34A1 PTH PHEX FGF23 ALB
21 calcinosis 29.7 SPP1 PHEX MGP KL GNAS GALNT3
22 osteitis fibrosa 29.6 PTH GNAS FGF23 CASR BGLAP
23 hyperthyroidism 29.5 PTH GNAS CRP BGLAP ALB
24 calciphylaxis 29.5 VDR PTH MGP FGF23 CASR ALB
25 bone disease 29.4 VDR SPP1 RUNX2 PTH PHEX FGF23
26 rickets 29.4 VDR SLC34A1 PTH PHEX KL FGF23
27 fibrous dysplasia 29.4 SPP1 GNAS FGF23 BGLAP
28 osteomalacia 29.4 VDR SLC34A1 SFRP4 PTH PHEX FGF23
29 hypophosphatasia 29.4 SPP1 RUNX2 PTH PHEX FGF23 BGLAP
30 end stage renal disease 29.3 VDR SPP1 PTH MGP KL FGF23
31 hypophosphatemic rickets, autosomal dominant 29.2 SLC34A1 SFRP4 PTH PHEX KL GALNT3
32 nephrocalcinosis 29.1 SPP1 SLC34A1 PHEX CASR
33 hypophosphatemia 29.1 VDR SPP1 SLC34A1 SFRP4 PTH PHEX
34 kidney disease 29.0 VDR SPP1 PTH MTOR MGP FGF23
35 primary hyperparathyroidism 28.9 VDR PTH KL GCM2 FGF23 CASR
36 vascular disease 28.9 SPP1 PTH MGP CRP ALB
37 uremia 28.8 VDR SPP1 RUNX2 PTH MGP CRP
38 hypophosphatemic rickets, x-linked dominant 28.7 SPP1 SLC34A1 SFRP4 PTH PHEX KL
39 chronic kidney disease 28.7 VDR SPP1 RUNX2 PTH MGP KL
40 bone resorption disease 28.5 VDR SPP1 RUNX2 PTH FGF23 CRP
41 aortic valve disease 1 28.3 SPP1 RUNX2 MGP BGLAP
42 diabetes mellitus 27.9 VDR SPP1 PTH MTOR KL FGF23
43 osteoporosis 27.1 VDR SPP1 SLC34A1 RUNX2 PTH MGP
44 tumoral calcinosis, hyperphosphatemic, familial, 2 11.1
45 tumoral calcinosis, hyperphosphatemic, familial, 3 11.1
46 hypoparathyroidism, familial isolated, 1 11.0
47 hypoparathyroidism, familial isolated, 2 11.0
48 hyperphosphatemia, polyuria, and seizures 11.0
49 pseudohypoparathyroidism, type ii 10.9
50 hypoparathyroidism, x-linked 10.9

Graphical network of the top 20 diseases related to Hyperphosphatemia:



Diseases related to Hyperphosphatemia

Symptoms & Phenotypes for Hyperphosphatemia

MGI Mouse Phenotypes related to Hyperphosphatemia:

46 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.43 ALB CRP FGF23 GALNT3 GNAS KL
2 homeostasis/metabolism MP:0005376 10.43 ALB BGLAP CASR CRP FGF23 GALNT3
3 cellular MP:0005384 10.42 ALB BGLAP CASR GALNT3 GCM2 GNAS
4 growth/size/body region MP:0005378 10.4 CASR FGF23 GALNT3 GNAS KL MGP
5 endocrine/exocrine gland MP:0005379 10.36 ALB BGLAP CASR FGF23 GALNT3 GCM2
6 immune system MP:0005387 10.34 ALB BGLAP CASR CRP FGF23 GALNT3
7 hematopoietic system MP:0005397 10.32 BGLAP CASR FGF23 GALNT3 GNAS KL
8 craniofacial MP:0005382 10.24 CASR GALNT3 GCM2 GNAS KL PHEX
9 mortality/aging MP:0010768 10.22 ALB CASR FGF23 GCM2 GNAS KL
10 digestive/alimentary MP:0005381 10.18 ALB CASR FGF23 GALNT3 KL PHEX
11 integument MP:0010771 10.06 CASR FGF23 GALNT3 GNAS KL RUNX2
12 limbs/digits/tail MP:0005371 10.02 FGF23 GALNT3 GNAS KL PHEX PTH
13 muscle MP:0005369 10 ALB CASR GALNT3 GNAS KL MGP
14 renal/urinary system MP:0005367 10 ALB CASR FGF23 GALNT3 GCM2 GNAS
15 skeleton MP:0005390 9.58 BGLAP CASR FGF23 GALNT3 GCM2 GNAS
16 respiratory system MP:0005388 9.56 FGF23 GNAS KL MGP MTOR RUNX2

Drugs & Therapeutics for Hyperphosphatemia

Drugs for Hyperphosphatemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 192)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Atorvastatin Approved Phase 4 134523-00-5 60823
2
Sodium citrate Approved, Investigational Phase 4 68-04-2
3
Nitroglycerin Approved, Investigational Phase 4 55-63-0 4510
4
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
5
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
6
Calcitriol Approved, Nutraceutical Phase 4 32222-06-3 5280453 134070
7 Lipid Regulating Agents Phase 4
8 Hypolipidemic Agents Phase 4
9 Anticholesteremic Agents Phase 4
10 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
11 Liver Extracts Phase 4
12 Citrate Phase 4
13 Anticoagulants Phase 4
14 Ferric Compounds Phase 4
15 Hematinics Phase 4
16 Vasodilator Agents Phase 4
17 Protective Agents Phase 4
18 Antioxidants Phase 4
19 Hormones Phase 4
20 Calcium, Dietary Phase 4
21 Nutrients Phase 4
22 Trace Elements Phase 4
23 Micronutrients Phase 4
24 Vitamins Phase 4
25 Vasoconstrictor Agents Phase 4
26
Calcium Nutraceutical Phase 4 7440-70-2 271
27
Parathyroid hormone Approved, Investigational Phase 3 9002-64-6
28
carbamide peroxide Approved Phase 3 124-43-6
29
Sevelamer Approved Phase 3 52757-95-6
30
Calcium acetate Approved, Investigational Phase 3 62-54-4
31
Iron Approved Phase 3 7439-89-6 23925 29936
32
Vitamin D Approved, Nutraceutical, Vet_approved Phase 3 1406-16-2
33 Calciferol Phase 3
34 Chelating Agents Phase 3
35 Pharmaceutical Solutions Phase 3
36 Bile Acids and Salts Phase 3
37
Guaifenesin Approved, Investigational, Vet_approved Phase 2 93-14-1 3516
38
Phenylpropanolamine Approved, Vet_approved, Withdrawn Phase 2 14838-15-4 26934
39
Calcium carbonate Approved, Investigational Phase 2 471-34-1
40
Vitamin D3 Approved, Nutraceutical Phase 2 67-97-0 5280795 6221
41
Ergocalciferol Approved, Nutraceutical Phase 2 50-14-6 5280793
42
Chitosan Experimental Phase 2 9012-76-4 71853
43 Chlorpheniramine, phenylpropanolamine drug combination Phase 2
44 Vitamin D2 Phase 2
45 Hepcidins Phase 2
46 Ergocalciferols Phase 2
47 Gastrointestinal Agents Phase 2
48 Antacids Phase 2
49 Anti-Ulcer Agents Phase 2
50 Polystyrene sulfonic acid Phase 1, Phase 2

Interventional clinical trials:

(show top 50) (show all 142)
# Name Status NCT ID Phase Drugs
1 The Efficacy and Safety of Nicotinic Acid in the Hemodialysis Patients With Hyperphosphatemia Unknown status NCT02836184 Phase 4 Nicotinic Acids;Calcium Carbonate
2 The Efficacy and Safety of Niacin on Hyperphosphatemia in End Stage Renal Disease Patients Undergoing Haemodialysis Unknown status NCT03163576 Phase 4 Niacin;Phosphate Binder
3 The Effect of Ferric Citrate on Inflammation and Lipid Levels in Patients on Hemodialysis Unknown status NCT02661295 Phase 4 Ferric Citrate
4 CARE-2 (Calcium Acetate (PhosLo®)/Sevelamer(Renagel®) Evaluation Study 2) Completed NCT00211939 Phase 4 calcium acetate;sevelamer;atorvastatin
5 Long Term Evaluation of Sevelamer HCl vs. Calcium-based Phosphate Binder in the Treatment of Hyperphosphatemia in Hemodialysis Patients Completed NCT01755078 Phase 4 Sevelamer HCl;Calcium-based phosphate binder
6 A Phase IV, Open-Label, Multi-Center Trial Evaluating the Efficacy of Fosrenol Compared to Existing Therapy in Adults With End Stage Renal Disease Treated for Hyperphosphatemia Completed NCT00160121 Phase 4 Lanthanum carbonate
7 Transition to Ferric Citrate Among Hemodialysis and Peritoneal Dialysis Patients: A Phase 4 "Real World" Experience Study From Kaiser Permanente Southern California Completed NCT03079869 Phase 4 Ferric Citrate
8 Phosphate Kinetic Modeling 2 Completed NCT01252771 Phase 4
9 A Long-Term, Open-Label, Prospective Phase IV Study to Assess the Safety and Efficacy of Nephoxil® in Subjects With End Stage Renal Disease (ESRD) on Dialysis Completed NCT03256838 Phase 4 Ferric Citrate
10 Randomized Open-Label Study to Evaluate Tenapanor as the Core Therapy in the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Who Are Phosphate Binder Naive or on Phosphate Binders to Optimize Phosphorus Management Recruiting NCT04549597 Phase 4 Tenapanor
11 Effect of Velphoro on Serum Phosphate and Albumin in Peritoneal Dialysis Patients Recruiting NCT04046263 Phase 4 Sucroferric Oxyhydroxide Chewable Tablet
12 Phosphate Lowering to Treat Vascular Dysfunction in Chronic Kidney Disease Active, not recruiting NCT02209636 Phase 4 Lanthanum carbonate;placebo;Ascorbic Acid;Nitroglycerin
13 A Long-Term, Open Label Study to Evaluate the Ability of Tenapanor Alone or in Combination With Sevelamer to Treat to Goal Serum Phosphorus in Patients With End-Stage Kidney Disease on Dialysis (NORMALIZE) Active, not recruiting NCT03988920 Phase 4 Tenapanor;Sevelamer Carbonate
14 Lanthanum Carbonate Versus Calcium Carbonate for Vascular Abnormalities in Patients With Chronic Kidney Disease and Hyperphosphatemia Enrolling by invitation NCT02237534 Phase 4 Lanthanum carbonate;Calcium Carbonate
15 A Randomized, Prospective, Cross-Over Study of Calcitriol vs. Paricalcitol in the Treatment of Mineral and Bone Disease in Hemodialysis Patients Terminated NCT01725113 Phase 4 Calcitriol;Paricalcitol
16 Effect of Non-calcium Phosphate Binders Versus Calcium Based Binders on Chronic Kidney Disease -Mineral and Bone Disorder in Children on Regular Hemodialysis Unknown status NCT03202407 Phase 3 Calcium acetate and sevelamer hydrochloride
17 A Phase 3, Long-term Study in Patients With Chronic Kidney Disease (CKD) and Hyperphosphatemia on Hemodialysis Completed NCT00892749 Phase 3 ASP1585
18 A Phase III Study of PA21 in Peritoneal Dialysis Patients With Hyperphosphatemia Completed NCT01852682 Phase 3 PA21
19 A Phase III Study of PA21 With Calcium Carbonate in Hemodialysis Patients With Hyperphosphatemia Completed NCT01850641 Phase 3 PA21
20 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-center, Withdrawal Study Comparing MCI-196 v.s Placebo Following A 12-Week Dose Titration Period With MCI-196 in Stage V Subjects on Dialysis With Hyperphosphatemia Completed NCT00506441 Phase 3 MCI-196;Placebo
21 A Randomized, Double Blind, Parallel Group Study For Assessing The Efficacy And Safety Of Renvela® Tablets For The Treatment Of Hyperphosphatemia In Patients With Chronic Kidney Disease Not On Dialysis Versus Placebo Completed NCT03001011 Phase 3 Placebo;Sevelamer Carbonate (GZ419831)
22 A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Tenapanor as Adjunctive Therapy to Phosphate Binder Therapy in End-Stage Renal Disease (ESRD) Subjects With Hyperphosphatemia Completed NCT03824587 Phase 2, Phase 3 Tenapanor;Placebo;Phosphate Binder Agents
23 A Phase III Study of PA21 in Hemodialysis Patients With Hyperphosphatemia Completed NCT01850602 Phase 3 PA21;Sevelamer hydrochloride
24 An Open-label, Long-term Extension Study of Lanthanum Carbonate 750 to 2,250 mg in Hyperphosphatemia in Patients With Chronic Kidney Disease Not on Dialysis (52 Weeks Extension From Study 14817) Completed NCT01187628 Phase 3 Fosrenol (Lanthanum Carbonate, BAY77-1931)
25 A Multicenter, Randomized, Open-Label, Active-Controlled, Parallel Study to Assess the Efficacy and Safety of Ferric Citrate Capsules for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemodialysis Completed NCT03984760 Phase 3 Ferric Citrate;Sevelamer Carbonate
26 A Phase III, Randomised, Double-Blind, Multi-centre, Withdrawal Study Comparing MCI-196 Versus Placebo in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia Completed NCT00416520 Phase 3 MCI-196 (Colestilan(INN), Colestimide(JAN), CHOLEBINE®);Placebo;Another phosphate binder (Sevelamer)
27 A Long-term Study of PA21 in Hemodialysis Patients With Hyperphosphatemia Completed NCT01833494 Phase 3 PA21
28 Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Lanthanum Carbonate 750 to 2250 mg in Patients With Chronic Kidney Disease Not on Dialysis Who Develop Hyperphosphatemia Completed NCT01110629 Phase 3 Fosrenol (Lanthanum Carbonate, BAY77-1931);Placebo
29 A Phase 3, Multicenter, Open-label, Sevelamer Hydrochloride-controlled Study in Chronic Kidney Disease (CKD) Patients With Hyperphosphatemia on Hemodialysis Completed NCT01057407 Phase 3 ASP1585;Sevelamer hydrochloride
30 Phase III Open Study of BAY 77 1931 (Lanthanum Carbonate) in Patients With Hyperphosphatemia Undergoing Continuous Ambulatory Peritoneal Dialysis (CAPD) Completed NCT01518387 Phase 3 Lanthanum Carbonate (BAY77-1931)
31 Phase III Double-blind Comparative Study of BAY 77 1931 (Lanthanum Carbonate) With a Calcium Carbonate in Patients With Hyperphosphatemia Undergoing Hemodialysis Completed NCT01514851 Phase 3 Lanthanum carbonate (BAY77-1931);Calcium carbonate
32 An 8-week, Multicenter, Randomized, Double-Blind, Parallel Group Study With a 4-week, Placebo-Controlled, Randomized Withdrawal Period to Evaluate the Efficacy, Safety, and Tolerability of Tenapanor to Treat Hyperphosphatemia in End-Stage Renal Disease Patients on Hemodialysis (ESRD-HD) Completed NCT02675998 Phase 3 Tenapanor;Placebo
33 ASP1585 Phase 3 Long-term Study in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis Completed NCT01742611 Phase 3 ASP1585
34 A Phase 3 Study in Patients With Chronic Kidney Disease (CKD) With Hyperphosphatemia on Peritoneal Dialysis Completed NCT01017276 Phase 3 ASP1585
35 A 26-Wk, Phase 3, Open Label Study With a 12-Wk, Placebo-Controlled, Randomized Withdrawal Period Followed by an Open Label Long Term Safety Extension to Evaluate the Safety and Efficacy of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on Dialysis Completed NCT03427125 Phase 3 Tenapanor;Placebo;Sevelamer Carbonate
36 A Phase III, Multi-center, Open Label, Flexible Dose, Long Term Safety Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia Completed NCT00772382 Phase 3 MCI-196
37 ASP1585 Phase 3 Randomized Double Blind Placebo-controlled Study in Chronic Kidney Disease (CKD) Patients With Hyperphosphatemia Not on Dialysis Completed NCT01742585 Phase 3 ASP1585;placebo
38 A Phase III, Multicentre, Open Label, Flexible Dose, Long Term Safety Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia Completed NCT00542815 Phase 3 MCI-196;Another Phosphate binder (Sevelamer)
39 A Phase III, Multi-centre, Double-blind, Randomised, Placebo-controlled Multiple Fixed-dose Study of MCI-196 Versus Placebo in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia and Dyslipidaemia (Incorporating Two Parallel High Dose Groups) Completed NCT00542386 Phase 3 MCI-196;Placebo
40 A Three-Period, 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD) on Dialysis Completed NCT01191255 Phase 3 ferric citrate, ca acetate, sevelamer carbonate, placebo
41 A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Definitive Phase III Study of the Effects of Ferric Citrate on Serum Phosphate in Subjects With End Stage Renal Disease Completed NCT01503736 Phase 3 ferric citrate;ferric citrate;ferric citrate
42 A Double-blind, Randomized, Placebo-controlled Multi-center Trial to Compare the Phosphate Lowering Efficacy of Different Doses of SBR759 to Placebo Completed NCT01069692 Phase 3 SBR759A;SBR759A;SBR759A;SBR759A;SBR759A
43 EPIC (Effect of PhosLo on Phosphorus Levels in Chronic Kidney Disease): A Prospective, Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Parallel Arm, Study of PhosLo on Phosphorus Levels in Subjects With Chronic Kidney Disease Completed NCT00211978 Phase 3 calcium acetate;placebo
44 A 4-Week Dose-Ranging and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD) Following a Two-Week Washout Period Completed NCT01074125 Phase 3 ferric citrate
45 Study to Investigate Efficacy and Safety Equivalence of OsvaRen® Tablets and OsvaRen® Granules Completed NCT02027662 Phase 2, Phase 3 Osvaren Granules;Osvaren film-coated tablets
46 A Two-Arm, Open-Label, Standard of Care Control Evaluation of Ferric Citrate for the Transition From Chronic Kidney Disease Stage 4/5 to Chronic Kidney Stage 5D Completed NCT02492620 Phase 3 Ferric Citrate
47 An Open-label, Randomised, Active-controlled, Parallel Group, Multicentre, Phase 3 Study to Investigate the Safety and Efficacy of PA21 and Sevelamer Carbonate (Renvela®) in Chinese CKD Patients With Hyperphosphataemia Completed NCT03644264 Phase 3 PA21;sevelamer carbonate
48 An Open Label, Dose Titration of Sevelamer Carbonate Tablets Dosed Three Times a Day in Hyperphosphatemic Chronic Kidney Disease Patients Not On Dialysis Completed NCT00681941 Phase 3 Sevelamer carbonate (Renvela®)
49 Outcome Study of Lanthanum Carbonate Compared With Calcium Carbonate on Cardiovascular Mortality and Morbidity in Patients With Chronic Kidney Disease on Hemodialysis (CKD5D) Completed NCT01578200 Phase 3 Lanthanum Carbonate;Calcium Carbonate
50 A Long-Term Safety Extension Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD) on Dialysis Completed NCT01554982 Phase 3 ferric citrate

Search NIH Clinical Center for Hyperphosphatemia

Cochrane evidence based reviews: hyperphosphatemia

Genetic Tests for Hyperphosphatemia

Genetic tests related to Hyperphosphatemia:

# Genetic test Affiliating Genes
1 Hyperphosphatemia 29

Anatomical Context for Hyperphosphatemia

MalaCards organs/tissues related to Hyperphosphatemia:

40
Kidney, Bone, Smooth Muscle, Endothelial, Colon, Liver, Whole Blood

Publications for Hyperphosphatemia

Articles related to Hyperphosphatemia:

(show top 50) (show all 3447)
# Title Authors PMID Year
1
Targeted deletion of the Nesp55 DMR defines another Gnas imprinting control region and provides a mouse model of autosomal dominant PHP-Ib. 54 61
20427744 2010
2
The fibroblast growth factor 23: a new player in the field of cardiovascular, bone and renal disease. 54 61
20180772 2010
3
Clinical variability of familial tumoral calcinosis caused by novel GALNT3 mutations. 54 61
20358599 2010
4
Recent advances in renal phosphate handling. 61 54
20177401 2010
5
Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy? 61 54
19965540 2010
6
Mapping of human autoantibody binding sites on the calcium-sensing receptor. 54 61
19580466 2010
7
In vivo genetic evidence for suppressing vascular and soft-tissue calcification through the reduction of serum phosphate levels, even in the presence of high serum calcium and 1,25-dihydroxyvitamin d levels. 54 61
20031638 2009
8
The journey from vitamin D-resistant rickets to the regulation of renal phosphate transport. 61 54
19808223 2009
9
Emerging topics in pediatric bone and mineral disorders 2008. 54 61
19615558 2009
10
[Chronic kidney disease (CKD) and bone. Vascular calcification in CKD]. 54 61
19329835 2009
11
[Disturbance of phosphorus metabolism in chronic kidney disease]. 54 61
19182354 2009
12
Vascular calcification in chronic kidney disease: pathogenesis and clinical implications. 54 61
19121777 2009
13
Impact of disturbances of calcium and phosphate metabolism on vascular calcification and clinical outcomes in patients with chronic kidney disease. 61 54
19295198 2009
14
An adolescent boy with thalassemia major presenting with bone pain, numbness, tetanic contractions and growth and pubertal delay: panhypopituitarism and combined vitamin D and parathyroid defects. 61 54
19337171 2008
15
Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. 54 61
18687639 2008
16
The mechanism of phosphorus as a cardiovascular risk factor in CKD. 54 61
18417722 2008
17
Bone mass does not correlate with the serum fibroblast growth factor 23 in hemodialysis patients. 54 61
17943081 2008
18
Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis. 54 61
17914251 2008
19
Fibroblast growth factor-23 is associated with parathyroid hormone and renal function in a population-based cohort of elderly men. 61 54
18166826 2008
20
Vitamin D receptor: key roles in bone mineral pathophysiology, molecular mechanism of action, and novel nutritional ligands. 61 54
18290715 2007
21
Regulatory mechanisms of circulating fibroblast growth factor 23 in parathyroid diseases. 54 61
17976083 2007
22
A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis. 61 54
17710231 2007
23
Advantage of a low glycemic index and low phosphate diet on diabetic nephropathy and aging-related diseases. 54 61
17878688 2007
24
Emerging role of fibroblast growth factor 23 in a bone-kidney axis regulating systemic phosphate homeostasis and extracellular matrix mineralization. 61 54
17565275 2007
25
Role of fibroblast growth factor 23 in phosphate homeostasis and pathogenesis of disordered mineral metabolism in chronic kidney disease. 54 61
17635819 2007
26
Fibroblast growth factor-23 (FGF23) in patients with transient hypoparathyroidism: its important role in serum phosphate regulation. 54 61
17464094 2007
27
Novel GALNT3 mutations causing hyperostosis-hyperphosphatemia syndrome result in low intact fibroblast growth factor 23 concentrations. 61 54
17311862 2007
28
Hyperostosis-hyperphosphatemia syndrome: a congenital disorder of O-glycosylation associated with augmented processing of fibroblast growth factor 23. 54 61
17129170 2007
29
Total parathyroidectomy with autotransplantation in patients with renal hyperparathyroidism: indications and surgical approach. 61 54
17178702 2006
30
Regulation of parathyroid function in chronic kidney disease (CKD). 61 54
17009074 2006
31
Osteopontin expression in vascular smooth muscle cells in patients with end-stage renal disease. 54 61
16817793 2006
32
[Familial tumoral calcinosis with hyperphosphatemia is heterogeneous and associated with mutations in GALNT3 or FGF-23]. 54 61
16733465 2006
33
Effect of manipulating serum phosphorus with phosphate binder on circulating PTH and FGF23 in renal failure rats. 61 54
16395276 2006
34
FGF-23 and sFRP-4 in chronic kidney disease and post-renal transplantation. 54 61
16691036 2006
35
[Effects of intermittent treatment with sevelamer hydrochloride on parathyroid hyperplasia and vascular calcification in rats with chronic kidney disease]. 61 54
16272627 2005
36
[Fibroblast growth factor (FGF)-23 in patients with hypoparathyroidism]. 61 54
16272628 2005
37
Fibroblast growth factor 23 and its receptors. 61 54
16076372 2005
38
Fibroblast growth factor-23 in patients with Graves' disease before and after antithyroid therapy: its important role in serum phosphate regulation. 61 54
15827108 2005
39
Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. 61 54
15917335 2005
40
An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. 54 61
15590700 2005
41
Hyperphosphatemia in renal failure. 61 54
15627730 2005
42
Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. 54 61
15579309 2004
43
FGF-23 is elevated by chronic hyperphosphatemia. 54 61
15356053 2004
44
Total parathyroidectomy reduces elevated circulating fibroblast growth factor 23 in advanced secondary hyperparathyroidism. 54 61
15332221 2004
45
Management of calcium and bone abnormalities in hemodialysis patients. 61 54
15490408 2004
46
What have we learnt about the regulation of phosphate metabolism? 54 61
15199289 2004
47
FGF-23 in patients with end-stage renal disease on hemodialysis. 54 61
15086938 2004
48
Vitamin D receptor and analogs. 61 54
14730505 2004
49
[The present state of vitamin D supplementation or treatment among chronic dialysis patients]. 61 54
15576951 2004
50
Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. 54 61
14633152 2003

Variations for Hyperphosphatemia

Expression for Hyperphosphatemia

Search GEO for disease gene expression data for Hyperphosphatemia.

Pathways for Hyperphosphatemia

GO Terms for Hyperphosphatemia

Cellular components related to Hyperphosphatemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.86 SPP1 SFRP4 PTH KL FGF23 CRP
2 Golgi apparatus GO:0005794 9.7 STX16 SPP1 PHEX MTOR GALNT3 BGLAP
3 perinuclear region of cytoplasm GO:0048471 9.43 STX16 SPP1 SLC34A1 PHEX GNAS GALNT3
4 extracellular region GO:0005576 9.32 SPP1 SFRP4 PTH MGP KL GNAS

Biological processes related to Hyperphosphatemia according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 10.02 VDR SFRP4 RUNX2 MTOR FGF23 CRP
2 cellular protein metabolic process GO:0044267 9.88 SPP1 SLC34A1 FGF23 ALB
3 cellular calcium ion homeostasis GO:0006874 9.83 VDR PTH GCM2 CASR
4 fibroblast growth factor receptor signaling pathway GO:0008543 9.77 KL GALNT3 FGF23
5 response to nutrient levels GO:0031667 9.77 PTH MTOR BGLAP
6 bone development GO:0060348 9.74 PHEX GNAS BGLAP
7 skeletal system development GO:0001501 9.73 VDR RUNX2 PTH PHEX GNAS BGLAP
8 biomineral tissue development GO:0031214 9.71 SPP1 SLC20A1 PHEX BGLAP
9 regulation of bone mineralization GO:0030500 9.69 MGP FGF23 BGLAP
10 energy reserve metabolic process GO:0006112 9.67 MTOR KL GNAS
11 cellular response to parathyroid hormone stimulus GO:0071374 9.63 SLC34A1 PHEX FGF23
12 vitamin D metabolic process GO:0042359 9.62 VDR FGF23
13 response to vitamin D GO:0033280 9.62 SPP1 PTH PHEX BGLAP
14 response to magnesium ion GO:0032026 9.61 SLC34A1 FGF23
15 phosphate ion transport GO:0006817 9.61 SLC34A1 SLC20A1
16 cellular phosphate ion homeostasis GO:0030643 9.61 SLC34A1 GCM2 FGF23
17 response to fibroblast growth factor GO:0071774 9.58 PTH CASR
18 positive regulation of MAPKKK cascade by fibroblast growth factor receptor signaling pathway GO:0090080 9.56 KL FGF23
19 response to sodium phosphate GO:1904383 9.55 PHEX FGF23
20 positive regulation of vitamin D 24-hydroxylase activity GO:0010980 9.54 VDR FGF23
21 response to parathyroid hormone GO:0071107 9.54 SLC34A1 PTH GNAS
22 cellular response to vitamin D GO:0071305 9.46 PHEX FGF23 CASR BGLAP
23 ossification GO:0001503 9.43 SPP1 SLC34A1 RUNX2 MGP CASR BGLAP
24 phosphate ion homeostasis GO:0055062 8.92 SLC34A1 SFRP4 PTH FGF23

Molecular functions related to Hyperphosphatemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 sodium:phosphate symporter activity GO:0005436 8.96 SLC34A1 SLC20A1
2 structural constituent of bone GO:0008147 8.62 MGP BGLAP

Sources for Hyperphosphatemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....